BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic sequencing; and mass spectrometry services, such as proteomic services and biologics characterization services. It also provides diagnostics and precision medicine, such as COVID-19 solutions, partnership opportunities, infectious diseases, and oncology services. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Zhao, Lijian

Employees

3,702

Website

www.bgi.com

IPO Date

2017-07-14

Headquarters

Building NO.7, BGI Park, No.21 Hongan 3rd Street, Yantian District, Shenzhen, Guangdong Province, 518083, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.